Validating an empiric sulfadiazine-trimethoprim dosage regimen for treatment of Escherichia coli and Staphylococcus delphini infections in mink (Neovison vison).
Animals
Anti-Infective Agents, Urinary
/ administration & dosage
Area Under Curve
Drug Combinations
Escherichia coli
/ drug effects
Escherichia coli Infections
/ drug therapy
Half-Life
Mink
Staphylococcal Infections
/ drug therapy
Staphylococcus
Sulfadiazine
/ administration & dosage
Trimethoprim
/ administration & dosage
Escherichia coli
Neovison vison
Staphylococcus delphini
mink
sulfadiazine
trimethoprim
Journal
Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
27
04
2020
revised:
21
06
2020
accepted:
02
07
2020
pubmed:
15
9
2020
medline:
12
8
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Antimicrobial agents are used extensively off-label in mink, as almost no agents are registered for this animal species. Pharmacokinetic (PK) and pharmacodynamic (PD) data are required to determine antimicrobial dosages specifically targeting mink bacterial pathogens. The aims of this study were to assess, in a PKPD framework, the empirical dosage regimen for a combination of trimethoprim (TMP) and sulfadiazine (SDZ) in mink, and secondarily to produce data for future setting of clinical breakpoints. TMP and SDZ PK parameters were obtained experimentally in 22 minks following IV or oral administration of TMP/SDZ (30 mg/kg, i.e. 5 mg/kg TMP and 25 mg/kg SDZ). fAUC/MIC with a target value of 24 hr was selected as the PKPD index predictive of TMP/SDZ efficacy. Using a modeling approach, PKPD cutoffs for TMP and SDZ were determined as 0.062 and 16 mg/L, respectively. By incorporating an anticipated potentiation effect of SDZ on TMP against Escherichia coli and Staphylococcus delphini, the PKPD cutoff of TMP was revised to 0.312 mg/L, which is above the tentative epidemiological cutoffs (TECOFF) for these species. The current empirical TMP/SDZ dosage regimen (30 mg/kg, PO, once daily) therefore appears adequate for treatment of wild-type E. coli and S. delphini infections in mink.
Substances chimiques
Anti-Infective Agents, Urinary
0
Drug Combinations
0
Sulfadiazine
0N7609K889
sulfadiazine, trimethoprim drug combination
39474-58-3
Trimethoprim
AN164J8Y0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-106Subventions
Organisme : Innovationsfonden
ID : 5189-00060B
Organisme : Danish fur breeder association
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Abu-Basha, E. A., Gehring, R., Hantash, T. M., Al-Shunnaq, A. F., & Idkaidek, N. M. (2009). Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). Journal of Veterinary Pharmacology and Therapeutics, 32(3), 258-263. https://doi.org/10.1111/j.1365-2885.2008.01036.x
Asín-Prieto, E., Rodríguez-Gascón, A., & Isla, A. (2015). Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. Journal of Infection and Chemotherapy, 21(5), 319-329. https://doi.org/10.1016/j.jiac.2015.02.001
Baert, K., De Baere, S., Croubels, S., & De Backer, P. (2003). Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. Veterinary Research Communications, 27(4), 301-309.
Baert, K., De Baere, S., Croubels, S., Gasthuys, F., & De Backer, P. (2001). Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim (trimazin 30%) after oral administration in non-fasted young pigs. Journal of Veterinary Pharmacology and Therapeutics, 24(4), 295-298. https://doi.org/10.1046/j.1365-2885.2001.00337.x
Bai, S. A., Walle, K., & Walle, T. (1985). Influence of food on the intravenous and oral dose kinetics of propranolol in the dog. Journal of Pharmacokinetics and Biopharmaceutics, 13(3), 229-241. https://doi.org/10.1007/BF01065654
Banker, M. J., & Clark, T. H. (2008). Plasma/serum protein binding determinations. Current Drug Metabolism, 9, 854-859.
Batzias, G. C., Delis, G. A., & Koutsoviti-Papadopoulou, M. (2005a). Bioavailability and Pharmacokinetics Of Sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep. Veterinary Research Communications, 29(8), 699-712. https://doi.org/10.1007/s11259-005-3868-6
Batzias, G. C., Delis, G. A., & Koutsoviti-Papadopoulou, M. (2005b). Bioavailability and pharmacokinetics of sulphadiazine, n 4 - acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine / trimethoprim combination in sheep. Veterinary Research Communications, 29, 699-712. https://doi.org/10.1007/s11259-005-3868-6
Bon, C., Toutain, P. L., Concordet, D., Gehring, R., Martin-Jimenez, T., Smith, J., … Mochel, J. P. (2018). Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics, 41(2), 171-183. https://doi.org/10.1111/jvp.12473.
Bushby, S. R. M. (1973). Trimethoprim-sulfamethoxazole: In vitro microbiological aspects. The Journal of Infectious Diseases, 128(Supplement_3), S442-S462. https://doi.org/10.1093/infdis/128.Supplement_3.S442.
Bushby, S. R. M. (1980). Sulfonamide and trimethoprim combinations. Journal of the American Veterinary Medical Association, 176(10), 1049-1053.
Bushby, S. R. M., & Hitchings, G. H. (1968). Trimethoprim, a sulphonamide potentiator. British Journal of Pharmacology and Chemotherapy, 33(1), 72-90. https://doi.org/10.1111/j.1476-5381.1968.tb00475.x.
Cheng, A. C., McBryde, E. S., Wuthiekanun, V., Chierakul, W., Amornchai, P., Day, N. P. J., … Peacock, S. J. (2009). Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. Antimicrobial Agents and Chemotherapy, 53(10), 4193-4199. https://doi.org/10.1128/AAC.01301-08.
CLSI (2019). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100, 29th ed. Wayne, PA: CLSI.
Drenkard, E. (2003). Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes and Infection, 5(13), 1213-1219. https://doi.org/10.1016/j.micinf.2003.08.009.
Ekström, B., Forsgren, U., Örtengren, B., & Bergan, T. (1979). Development of sulphonamide-trimethoprim combinations for urinary tract infections. Infection, 7(S4), S359-S366. https://doi.org/10.1007/BF01639014.
Elvin, A. T., Cole, A. F. D., Pieper, J. A., Rolbin, S. H., & Lalka, D. (1981). Effect of food on lidocaine kinetics: Mechanism of food-related alteration in high intrinsic clearance drug elimination. Clinical Pharmacology & Therapeutics, 30(4), 455-460. https://doi.org/10.1038/clpt.1981.188.
Greko, C., Bengtsson, B., Franklin, A., Jacobsson, S.-O., Wiese, B., & Luthman, J. (2002). Efficacy of trimethoprim-sulfadoxine against Escherichia coli in a tissue cage model in calves. Journal of Veterinary Pharmacology and Therapeutics, 25(6), 413-423. https://doi.org/10.1046/j.1365-2885.2002.00431.x.
Gustafsson, A., Baverud, V., Franklin, A., Gunnarsson, A., Ogren, G., & Ingvast-Larsson, C. (1999). Repeated administration of trimethoprim/sulfadiazine in the horse -pharmacokinetics, plasma protein binding and influence on the intestinal microflora. Journal of Veterinary Pharmacology and Therapeutics, 22(1), 20-26. https://doi.org/10.1046/j.1365-2885.1999.00183.x.
Høiby, N., Ciofu, O., & Bjarnsholt, T. (2010). Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiology, 5(11), 1663-1674. https://doi.org/10.2217/fmb.10.125.
Karlsson, M. O., & Savic, R. M. (2007). Diagnosing model diagnostics. Clinical Pharmacology & Therapeutics, 82(1), 17-20. https://doi.org/10.1038/sj.clpt.6100241.
Kielhofner, M. A. (1990). Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Texas Heart Institute Journal, 17(2), 86-93.
Köhler, T., Kok, M., Michea-Hamzehpour, M., Plesiat, P., Gotoh, N., Nishino, T., Pechere, J. C. (1996). Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 40(10), 2288-2290. https://doi.org/10.1128/AAC.40.10.2288
Lees, P., Aliabadi, M. H. S., & Toutain, P.-L. (2004). PK-PD modelling: an alternative to dose titration studies for antimicrobial drug dosage selection. Regulatory Affairs Journal, January, 175-180.
Mengelers, M. J. B., Hougee, P. E., Janssen, L. H. M., & Van Miert, A. S. J. P. A. M. (1997). Structure-activity relationships between antibacterial activities and physicochemical properties of sulfonamides. Journal of Veterinary Pharmacology and Therapeutics, 20(4), 276-283. https://doi.org/10.1046/j.1365-2885.1997.00063.x.
Mould, D. R., & Upton, R. N. (2012). Basic concepts in population modeling, simulation, and model-based drug development. cpt: pharmacometrics & systems. Pharmacology, 1(9), e6. https://doi.org/10.1038/psp.2012.4.
Mouton, J. W., Brown, D., Apfalter, P., Cantón, R., Giske, C. G., Ivanova, M., … Kahlmeter, G. (2012). The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical Microbiology and Infection, 18(3), E37-E45. https://doi.org/10.1111/j.1469-0691.2011.03752.x.
Mouton, J. W., Muller, A. E., Canton, R., Giske, C. G., Kahlmeter, G., & Turnidge, J. (2018). MIC-based dose adjustment: facts and fables. Journal of Antimicrobial Chemotherapy, 73(3), 564-568. https://doi.org/10.1093/jac/dkx427.
Muller, A. E., Theuretzbacher, U., & Mouton, J. W. (2015). Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clinical Microbiology and Infection, 21(10), 881-885. .1016/j.cmi.2015.06.007
Nielsen, P., & Gyrd-Hansen, N. (1994). Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. Research in Veterinary Science, 56(1), 48-52. https://doi.org/10.1016/0034-5288(94)90195-3.
Nikolaisen, N. K., Lassen, D. C. K., Chriél, M., Larsen, G., Jensen, V. F., & Pedersen, K. (2017). Antimicrobial resistance among pathogenic bacteria from mink (Neovison vison) in Denmark. Acta Veterinaria Scandinavica, 59(1), 60. https://doi.org/10.1186/s13028-017-0328-6.
Nimmo, W. S., & Peacock, J. E. (1988). Effect of anaesthesia and surgery on pharmacokinetics and pharmacodynamics. British Medical Bulletin, 44(2), 286-301. https://doi.org/10.1093/oxfordjournals.bmb.a072252.
Pedersen, K., Hammer, A. S., Sørensen, C. M., & Heuer, O. E. (2009). Usage of antimicrobials and occurrence of antimicrobial resistance among bacteria from mink. Veterinary Microbiology, 133(1-2), 115-122. https://doi.org/10.1016/j.vetmic.2008.06.005.
Sadaka, C., Kanellos, T., Guardabassi, L., Boucher, J., & Watts, J. L. (2017). Evaluation of veterinary-specific interpretive criteria for susceptibility testing of Streptococcus equi subspecies with trimethoprim-sulfamethoxazole and trimethoprim-sulfadiazine. Journal of Clinical Microbiology, 55(1), 326-330. https://doi.org/10.1128/JCM.01610-16.
Schwarz, S., L. M. Cavaco, J. Shen, & F. M. Aarestrup (Eds.) (2018). Antimicrobial resistance in bacteria from livestock and companion animals (First). Washington DC: ASM Press.
Shoaf, S. E., Schwark, W. S., & Guard, C. L. (1989). Pharmacokinetics of sulfadiazine/trimethoprim in neonatal male calves: effect of age and penetration into cerebrospinal fluid. American Journal of Veterinary Research, 50(3), 396-403. https://europepmc.org/abstract/med/2930028.
Sigel, C. W., Ling, G. V., Bushby, S. R., Woolley, J. L. Jr, DeAngelis, D., & Eure, S. (1981). Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration. American Journal of Veterinary Research, 42(6), 996-1001.
Toutain, P. L., Bousquet-Mélou, A., Damborg, P., Ferran, A. A., Mevius, D., Pelligand, L., … Lees, P. (2017). En route towards european clinical breakpoints for veterinary antimicrobial susceptibility testing: a position paper explaining the VetCAST approach. Frontiers in Microbiology, 8, 2344. https://doi.org/10.3389/fmicb.2017.02344.
Toutain, P.-L., Del Castillo, J. R. E., & Bousquet-Mélou, A. (2002). The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 73(2), 105-114. https://doi.org/10.1016/S0034-5288(02)00039-5.
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006). Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clinical Microbiology and Infection, 12(5), 418-425. https://doi.org/10.1111/J.1469-0691.2006.01377.X.
Van Duijkeren, E., Ensink, J. M., & Meijer, L. A. (2002). Distribution of orally administered trimethoprim and sulfadiazine into noninfected subcutaneous tissue chambers in adult ponies. Journal of Veterinary Pharmacology and Therapeutics, 25(4), 273-277. https://doi.org/10.1046/j.1365-2885.2002.00418.x.
Van Duijkeren, E., Vult, A. G., Oldruitenborgh-oosterbaan, M. M. S. V., Mevius, D. J., Kessels, B. G. F., Breukink, H. J., & Mierts, A. S. J. P. A. M. V. (1994). A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse. Journal of Veterinary Pharmacology and Therapeutics, 17(6), 440-446. https://doi.org/10.1111/j.1365-2885.1994.tb00275.x.
Van Miert, A. S. J. P. A. M. (1994). The sulfonamide-diaminopyrimidine story. Journal of Veterinary Pharmacology and Therapeutics, 17(4), 309-316. https://doi.org/10.1111/j.1365-2885.1994.tb00251.x.
Villa, R. E., Prandini, E., Caloni, F., & Carli, S. (1997). Serum protein binding of some sulfonamides, quinolones and fluoroquinolones in farm and domestic animals. Journal of Veterinary Pharmacology and Therapeutics, 20(suppl.1(60)), 34-35.
Yamaoka, K., Nakagawa, T., & Uno, T. (1978). Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics, 6(2), 165-175. https://doi.org/10.1007/BF01117450.